<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00802568</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000626720</org_study_id>
    <secondary_id>IPC-2005-002</secondary_id>
    <secondary_id>IPC-ITT 04-02</secondary_id>
    <secondary_id>EUDRACT-2005-01053-13</secondary_id>
    <secondary_id>INCA-RECF0428</secondary_id>
    <secondary_id>AMGEN-IPC-2005-002</secondary_id>
    <secondary_id>JANSSEN-IPC-2005-002</secondary_id>
    <nct_id>NCT00802568</nct_id>
  </id_info>
  <brief_title>Fludarabine, Busulfan, Antithymocyte Globulin, and Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma That Has Not Responded to Treatment</brief_title>
  <official_title>Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation Following Reduced Intensity Conditioning in Treating Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop&#xD;
      the growth of cancer cells. It also stops the patient's immune system from rejecting the&#xD;
      donor's stem cells. The donated stem cells may replace the patient's immune cells and help&#xD;
      destroy any remaining cancer cells (graft-versus-tumor effect).&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects of giving fludarabine together with&#xD;
      busulfan and antithymocyte globulin followed by donor stem cell transplant and to see how&#xD;
      well it works in treating patients with multiple myeloma that has not responded to treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To study the toxicity of reduced intensity conditioning comprising fludarabine&#xD;
           phosphate, busulfan, and anti-thymocyte globulin followed by allogeneic hematopoietic&#xD;
           stem cell transplantation in patients with refractory or relapsed multiple myeloma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To study the tumor response in these patients.&#xD;
&#xD;
        -  To study the incidence of acute or chronic graft-versus-host disease in these patients.&#xD;
&#xD;
        -  To study the incidence of infectious complications in these patients.&#xD;
&#xD;
        -  To study relapse- or progression-free and overall survival of these patients.&#xD;
&#xD;
        -  To study the biological mechanisms (i.e., taking graft, immunological recovery,&#xD;
           antitumor activity, and chimerism).&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive reduced intensity conditioning comprising fludarabine IV on days -5 to -1,&#xD;
      oral busulfan on days -4 and -3, and anti-thymocyte globulin IV on days -2 and -1. Patients&#xD;
      undergo allogeneic hematopoietic stem cell transplantation on day 0.&#xD;
&#xD;
      After completion of study therapy, patients are followed every month for 6 months and then&#xD;
      every 3 months for 1Â½ years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality rate at 1 year</measure>
  </primary_outcome>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>nonmyeloablative allogeneic hematopoietic stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of multiple myeloma, meeting 1 of the following criteria:&#xD;
&#xD;
               -  Stage I disease with a bone lesion&#xD;
&#xD;
               -  Stage II or III disease meeting any of the following criteria:&#xD;
&#xD;
                    -  Elevated beta-2 microglobulin&#xD;
&#xD;
                    -  Deletion of chromosome 13&#xD;
&#xD;
          -  Refractory or relapsed disease&#xD;
&#xD;
          -  Presence of an evaluable monoclonal component&#xD;
&#xD;
          -  Must have achieved reduction of primary tumor after receiving prior intensified&#xD;
             chemotherapy with high-dose melphalan and cyclosporine with autologous transplantation&#xD;
&#xD;
          -  HLA identical family donor available&#xD;
&#xD;
               -  Bone marrow transplantation is allowed in case hematopoietic stem cell collection&#xD;
                  fails&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
          -  No contraindications to allogeneic transplantation&#xD;
&#xD;
          -  No contraindications to drugs used in conditioning regimen&#xD;
&#xD;
          -  No psychiatric illness&#xD;
&#xD;
          -  No other cancer within the past 5 years except basal cell skin cancer or epithelioma&#xD;
             in situ of the cervix&#xD;
&#xD;
          -  No serious and uncontrolled infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 1 month since participation in another prior clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier Blaise, MD</last_name>
    <affiliation>Institut Paoli-Calmettes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>December 4, 2008</study_first_submitted>
  <study_first_submitted_qc>December 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2008</study_first_posted>
  <last_update_submitted>May 13, 2011</last_update_submitted>
  <last_update_submitted_qc>May 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2011</last_update_posted>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>osteolytic lesions of multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

